加载中
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
前收盘价
US$22.22
−US$1.95 · -8.07%
盘后
US$21.88
−US$0.34 · -1.53%
10月13日 19:53 ET
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
57
合理估值
情绪
70
看涨
风险
44
风险偏高
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
日内区间
当前US$22.22
52周区间
当前US$22.22
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6238.4万 USD | 4206.9万 USD | 3652.7万 USD | 2486万 USD | 3704.2万 USD |
| 销货成本 | 228.1万 USD | — | — | — | — |
| 毛利 | 6010.3万 USD | 4206.9万 USD | 3652.7万 USD | 2486万 USD | 3704.2万 USD |
| 研究与开发 | 1.32亿 USD | 1.44亿 USD | 1.15亿 USD | 1.06亿 USD | 7763.6万 USD |
| 销售、一般及管理费用 | 4150.8万 USD | 4374.6万 USD | 3550.2万 USD | 3002.5万 USD | 1759.6万 USD |
| 营业费用 | 1.71亿 USD | 1.88亿 USD | 1.51亿 USD | 1.36亿 USD | 9523.2万 USD |
| 利息收入 | 563万 USD | 789万 USD | 661.9万 USD | 145.6万 USD | 49.5万 USD |
| 折旧和摊销 | 228.1万 USD | 249.9万 USD | 241.5万 USD | 160.8万 USD | 89.7万 USD |
| 营业利润 | −1.11亿 USD | −1.46亿 USD | −1.14亿 USD | −1.11亿 USD | −5819万 USD |
| 净利润 | −1.02亿 USD | −1.3亿 USD | −1.02亿 USD | −1.08亿 USD | −5823.5万 USD |
公司数据更新于 2026年10月14日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1.02亿0.99%102.75亿 USD0.35%US$146.8-3.04%
Vanguard Morningstar Total Stock Market ETFVTI1.01亿0.00%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM8735.44万0.11%777.48亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF3284.46万0.03%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO3145.05万0.23%137.9亿 USD0.24%US$351.1-0.74%
iShares Biotechnology ETFIBB2625.29万0.24%107.38亿 USD0.44%US$200.02-2.08%
Vanguard Russell 2000 ETFVTWO1849.03万0.10%180亿 USD0.06%US$111.77-0.45%
Schwab U.S. Small-Cap ETFSCHA1846.39万0.09%217.13亿 USD0.03%US$32.56-0.31%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
